ArticleBMJ open diabetes research & care2022

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).

Hiroshi Nomoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.